Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Tamoxifen

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Tamoxifen

Preeti Patel et al.
Free Books & Documents

Excerpt

Tamoxifen is a selective estrogen receptor modulator used to treat breast cancer in various clinical settings. This drug is particularly effective for patients with estrogen receptor–positive tumors and is approved by the US Food and Drug Administration (FDA) for use in both females and males with breast cancer. Tamoxifen is also approved for various indications, including adjuvant therapy after surgery and radiation. Additional FDA-approved indications include the treatment of ductal carcinoma in situ in females, reducing the risk of invasive breast cancer, and breast cancer risk reduction in high-risk patients. Tamoxifen also has several off-label uses, some of which require further investigation. Tamoxifen exerts both estrogenic and anti-estrogenic effects depending on the tissue. The drug inhibits tumor growth in breast tissue while acting as an estrogen agonist in bone, which may help prevent osteoporosis in postmenopausal women. Tamoxifen is a first-line option for hormone receptor-positive metastatic breast cancer and remains a key treatment for men with hormone receptor-positive disease.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Tibb Jacobs declares no relevant financial relationships with ineligible companies.

Similar articles

References

    1. Quirke VM. Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation. Front Pharmacol. 2017;8:620. - PMC - PubMed
    1. Brufsky AM, Dickler MN. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist. 2018 May;23(5):528-539. - PMC - PubMed
    1. Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2024 Jan;10:e2300285. - PMC - PubMed
    1. Eggemann H, Altmann U, Costa SD, Ignatov A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J Cancer Res Clin Oncol. 2018 Feb;144(2):337-341. - PMC - PubMed
    1. Gradishar W, Salerno KE. NCCN Guidelines Update: Breast Cancer. J Natl Compr Canc Netw. 2016 May;14(5 Suppl):641-4. - PubMed

Publication types

LinkOut - more resources